A 54-year-old woman with suspicion of neuroendocrine tumor (NET) was referred for 68 Ga-DOTATATE positron emission tomography/computed tomography (CT) imaging due to clinical findings. A well-defined osteolytic lesion on the corpus of the third lumbar vertebra was evident on CT images with mild uptake of 68 Ga-DOTATATE, which led to suspicion of NET metastasis. Histopathologic examination revealed solitary plasmacytoma of the bone. The patient received local external radiotherapy for plasmacytoma. This case indicatesthat other diseases expressing somatostatin receptors may be inaccurately reported as tumor recurrence and highlights the importance of meticulous evaluation of positive findings. Keywords: 68 Ga-octreotide, DOTA(0)-Tyr(3)-, positron emission tomography/computed tomography, plasmacytoma, neuroendocrine tumors
Introduction
The primary indication of 68 Ga-DOTA-conjugated peptide positron emission tomography/computed tomography (PET/ CT) is neuroendocrine tumor (NET) imaging (1) . However, tumors that express somatostatin (SST) receptors other than NETs can also be visualized by 68 Ga-DOTA-conjugated peptide PET/CT (2) . In vitro studies with plasma cell lines have shown that the SST is expressed on malignant plasma cells (3) . In our case, a solitary bone plasmacytoma (SBP) in the lumbar spine showed increased 68 Ga-DOTATATE uptake mimicking bone metastasis in a patient with suspected NET recurrence. SBP is characterized by a solitary bone lesion that shows infiltration by plasma cells without evidence of anemia, hypercalcemia, or renal involvement suggesting systemic myeloma (4) . SBP may involve any bone but most often affects the axial skeleton, particularly the vertebra, pelvis, ribs and pectoral girdle (4).
Case Report
A 54-year-old woman with suspicion of NET was referred for 68 Ga-DOTATATE PET/CT due to clinical findings. A welldefined osteolytic lesion on the corpus of the third lumbar vertebra extending to the right pedicle was evident on CT images (Figure 1a 
Literature Review and Discussion
68 Ga-DOTA-conjugated peptide PET/CT is the imaging modality of choice for NETs for the detection of metastatic disease or local relapse, and it affects therapeutic approach in more than 40% of patients (5, 6, 7) . The most common sites of NET metastasis are the liver, lymph nodes and bone (8) . The presence of bone metastasis has vital clinical importance on treatment management, since it has been shown that bone metastasis is associated with poor overall survival (6) . Although results of 68 Ga-DOTA-conjugated peptide PET/ CT in NETs are remarkable other tumors that express SST (predominantly SST2, SST3 and SST5), such as lymphomas, breast and lung cancers, thyroid cancers, gastrointestinal stromal tumors, prostate cancers and plasmacytoma/ multiple myelomas, can also be avid for 68 Ga-DOTAconjugated peptide PET/CT, thus misleading the physician (2). It is not unusual that SBP has avidity of 68 Ga-DOTATATE. Previous studies have shown that 111 In-pentetreotide SST scintigraphy is an alternative method to displayin vivo multiple myeloma/SBP activity, especially in patients with relapsing disease and a more aggressive type of myeloma (9) . In our case, a solitary osteolytic vertebral lesion with mild 68 Ga-DOTATATE uptake is less likely to be a metastasis because skeletal lesions of NETs are mostly osteosclerotic. The metastasis due to NETs are osteolytic only in 10% of the cases (10) . A histopathologic evaluation was required for the definite diagnosis of the bone lesion and the patient was diagnosed with SBP, not relapse. Degenerative diseases in the spine can also lead to increased 68 Ga-DOTATATE uptake. Klinaki et al. (11) In the literature, there aretwo case reports describing 68 Ga-DOTATATE avid vertebral hemangiomas (13, 14 
